Urolithin A and muscle endurance in older adults, 65-90 (Liu et al., 2022)
Human RCT — functional endpoint
Record verify: verified against primary source
| Design | Randomized, double-blind, placebo-controlled trial (functional/biomarker) |
| DOI | 10.1001/jamanetworkopen.2021.44279 |
| Citation status | doi verified via Crossref 2026-07-12 (JAMA Netw Open 2022;5(1):e2144279, Liu et al., 'Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults'). PMID and trial registry ID are not confirmed; see identifier status. |
Identifiers: DOI verified; PMID not reported; trial registry id not reported. Record-level verification and identifier-level status are separate: a record can be verified against its primary publication on one identifier while another is simply not confirmed. No identifier is fabricated, and none is left in a “pending” state.
Five-qualifier claim
| Species / population | Older adults aged 65-90 (randomized, placebo-controlled trial). |
| Exposure, route, schedule | Oral urolithin A (1000 mg/day) for 4 months. |
| Comparator / duration | Placebo-controlled, randomized, double-blind; 4-month intervention. |
| Endpoint / numeric result | Improved a muscle-endurance measure and some plasma mitochondrial biomarkers; several endpoints (e.g. 6-minute walk distance, muscle ATP) did NOT reach statistical significance. |
| What it did NOT establish | Mixed functional/biomarker result; no lifespan, disease-outcome, or healthy-aging-longevity claim is supported. |
Interventions
What this trial administered
These are the compounds this trial administered, nothing more. MitoiX does not rank products, name a best one, or suggest a dose — read the record above and the primary reference, then talk to a clinician.
- Urolithin A (Mitopure) — Urolithin A (Mitopure)
Studied form: Mitopure, 500-1000 mg/day in the human trials
Find Urolithin A (Mitopure) on Amazon →
Links marked with an arrow are affiliate links: MitoiX may earn a commission if you buy through them, at no extra cost to you. This never affects what is published — see the affiliate disclosure.
Primary reference
https://doi.org/10.1001/jamanetworkopen.2021.44279
Exact identifier confirmed against the primary record via Crossref/ClinicalTrials.gov where stated in the citation status names the source and the date. An identifier that is not confirmed is named as such in the identifier row above, never filled in from a secondary source.